Single-Use Bioreactors Market Size to Envision USD 22.46 Billion by 2034
The global single-use bioreactors market is valued at USD 5.38 billion in 2025 and is projected to expand to approximately USD 22.46 billion by 2034, advancing at a CAGR of 17.21% during the forecast period.
Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global single-use bioreactors market size was valued at USD 4.59 billion in 2024 and is projected to reach approximately USD 22.46 billion by 2034, growing at a CAGR of 17.21%, according to a study by Towards Healthcare, a sister company of Precedence Research.
The accelerating demand for cell therapies and tailored medicine is contributing to the growth of the single-use bioreactors market.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5447
Key Takeaways
- North America was dominant in the market share by 35% in 2024.
- Asia Pacific is expected to grow at the fastest CAGR during 2025-2034.
- By product, the single-use bioreactor systems segment led the market in 2024.
- By product, the single-use media bags segment is expected to witness significant expansion in the studied years.
- By type, the stirred tank SUBs segment dominated the market in 2024 and is expected to grow rapidly in the upcoming years.
- By cell type, the mammalian cells segment registered dominance in the single-use bioreactors market in 2024.
- By cell type, the bacterial cells segment is expected to grow at a notable CAGR in the predicted timeframe.
- By molecule type, the vaccines segment captured the largest share of the market in 2024.
- By molecule type, the gene modified cells segment is expected to register the fastest expansion during the forecast period.
- By application, the research and development (R&D) or process development segment led the market in 2024.
- By application, the bioproduction segment is expected to be the fastest-growing during 2025-2034.
- By usage, the lab-scale production segment led the single-use bioreactors market in 2024.
- By usage, the large-scale production segment is expected to grow significantly in the projected period.
- By end-use, the CMOs & CROs segment held a major revenue share of the market in 2024.
- By end-use, the pharmaceutical and biopharmaceutical companies segment is expected to register significant growth during 2025-2034.
Market Overview & Potential
Primarily, single-use bioreactors are disposable, pre-sterilized bioreactors established for cell culture and microbial fermentation. Furthermore, providing benefits, including minimized contamination risk, minimal capital expenditure, and quicker turnaround times compared to conventional stainless steel systems. The single-use bioreactors market possesses numerous applications in the biopharmaceutical industry for the manufacturing of different biologics like vaccines, monoclonal antibodies, and recombinant proteins. Besides this, in 2025, the market will boost automation, scalability, and process control, with the launch of novel models and features.
Report Scope
| Metric | Details | |
| Market Size in 2024 | USD 4.59 Billion | |
| Projected Market Size in 2034 | USD 22.46 Billion | |
| CAGR (2025 - 2034) | 17.21 | % |
| Leading Region | North America | |
| Market Segmentation | By Product, By Type, By Type of Cell, By Molecule Type, By Application, By Usage Type, By End-use, By Region | |
| Top Key Players | Sartorius Stedim Biotech, Thermo Fisher Scientific, Danaher, Merck KgaA, Celltainer Biotech BV, Getinge AB, Eppendorf AG, Cellexus, PBS Biotech Inc., Distek Inc., ABEC, Able Corporation & Biott Corporation, G&G Technologies Inc., Solida Biotech GmbH, Satake Chemical Equipment Mfg., Ltd., Stobbe Pharma GmbH, bbi-biotech GmbH | |
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Key Drivers in the Developing Market?
Across the single-use bioreactors market, several factors contribute to the expansion, such as it has affordability and enhanced efficiency. Other drivers involved in the comprehensive development of the market are the growing innovations in bioreactor design and the emergence of large-scale single-use bioreactors. Apart from this, the rising demand for diverse biologics, like monoclonal antibodies, vaccines, and cell & gene therapies, is fueling the adoption of single-use bioreactors.
What are the Trends in the Single-Use Bioreactors Market?
The market is experiencing major growth due to accelerating pharmaceutical R&D expenses and the movement towards sustainable manufacturing practices.
- In March 2025, the collaboration, named Project Nexus, secured £1.4 million in funding from Innovate UK’s Sustainable Medicines Manufacturing Innovation, focused on cultivating new sustainable materials customized for single-use bioprocessing equipment, like bioreactors.
- In June 2024, AGC Biologics expanded its single-use bioreactor capacity with progression at the Denmark site.
What Is the Arising Challenge in the Market?
In the single-use bioreactors market, challenges are developing hurdles in its expansion, such as a consistent requirement for single-use components like bags, filters, etc. accelerate the expenses. Besides this, issues regarding the consistency and reliability of performance from one single-use bag to another, possibly impacting batch-to-batch reproducibility, are another barrier in numerous pharmaceutical companies.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
Why Did North America Dominate the Market in 2024?
In 2024, North America captured the largest revenue share of 35% in the single-use bioreactors market. Due to affordability and rapid turnaround times, reduced cleaning and validation requirements are assisting in the adoption of single-use bioreactors in this region. Along with this, expanding demand and production for biologics, especially monoclonal antibodies, vaccines, and cell and gene therapies, are propelling in the leading pharmaceutical companies of this region. This further supports a rise in efficiency and scalability scalable manufacturing solutions.
For instance,
- In August 2025, Cytiva collaborated with Culture Biosciences, which specializes in cloud-connected bioreactor technology, to support both hardware commercialization and technology development.
- In January 2025, Sartorius and McMaster University opened a Canadian bioprocessing hub of about a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto.
- In October 2024, Recipharm and Exela collaborated to expand US sterile injectable production.
How is Asia Pacific Growing in Single-use Bioreactors Market?
During 2025-2034, the Asia Pacific is anticipated to expand at the fastest CAGR in the single-use bioreactors market. In the ASAP countries, such as China and India, are actively involved in the investment in biopharmaceutical research and development activities, which are further assisting in the emergence of the single-use bioreactors in various bioprocessing. Alongside, Contract Manufacturing Organizations (CMOs) of ASAP are widely adopting single-use bioreactors to enable feasible manufacturing solutions and minimal cross-contamination risks. Adaptable government policies and incentives focused on the development of the biotechnology sector in ASAP countries are further accelerating the market growth.
For instance,
- In June 2025, Hyderabad-based Biological E Limited (BE) partnered with China’s Jiangsu Recbio Technology Company Limited to manufacture and distribute a 9-valent Human Papillomavirus (HPV9) vaccine.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Segmental Insights
By product analysis
How did the Single-Use Bioreactor Systems Dominate the Market in 2024?
The single-use bioreactor systems segment registered dominance in the single-use bioreactors market in 2024. The segment is driven by the growing production of biologics and biosimilars. Moreover, many advantages of this system, such as its flexibility, scalability, affordability, and minimal chances of cross-contamination, are influencing overall market growth. Along with this, single-use bioreactors use less water and energy for their operation.
On the other hand, the single-use media bags segment is estimated to grow significantly during 2025-2034. These bags are broadly employed in the preparation and storage of sterile media and buffers, which are necessary for cell proliferation and other bioprocessing stages. Also, they are a feasible and effective approach to manage crucial fluids, with the elimination of requirement for need for conventional stainless steel tanks and associated cleaning processes. Along with this, single-use bags are employed in conjunction with chromatography systems in the separation and purification of target molecules.
By type analysis
Why did the Stirred Tank Subs Segment Lead the Market in 2024?
The stirred tank SUBs segment was dominant in the market in 2024 and is estimated to grow at a rapid CAGR in the single-use bioreactors market. This type of bioreactor possesses superior mixing and aeration capabilities, which are important for high-density cell cultures. Involvement of this type of bioreactor in biopharmaceutical manufacturing of monoclonal antibody (MAb) therapies and other biological products is driving the overall segment’s growth. Apart from this, stirred tank SUBs have a vital significance in scale-up processes from R&D to production, allied with their inexpensive and minimized risk of contamination.
By cell type analysis
Which Cell Type Led the Single-Use Bioreactors Market in 2024?
The mammalian cells segment held a dominant revenue share of the market in 2024. These types of cells are widely used in the production of complex biologics, including monoclonal antibodies and therapeutic proteins, which are in increasing demand for advanced therapies. This ultimately enhances the adoption of single-use bioreactors. Also, mammalian cells play a crucial role in expressing functional enzymes for therapeutic applications, including enzyme replacement therapies. Eventually, mammalian cells like BHK-21, Vero, and MDCK are applied in the production of viral vaccines for both human and veterinary applications.
Whereas, the bacterial cells segment is estimated to witness significant growth during 2025-2034. Widespread applications of bacterial cells in the biopharmaceutical production, like recombinant protein production, are fueling demand for single-use bioreactors to achieve an essential target. In the case of recombinant protein production, bacterial expression systems such as E. coli are incorporated to accelerate the development of insulin and other therapeutic proteins. Derivatives of bacterial antigens are immensely used in vaccine development.
By molecule type analysis
What Made the Vaccines Segment Dominant in the Market in 2024?
In the single-use bioreactors market, the vaccines segment accounted for a major share in 2024. Varied aspects of single-use bioreactors in vaccine development mainly comprise their rapid product development cycles and quicker turnaround times. Moreover, they have decreased risk of cross-contamination among batches, which ultimately ensures greater product purity and consistency, which is impacting as an important aspect in vaccine production. One of the significant factors, such as raising investments in the pharmaceutical R&D sector, is boosting the adoption of single-use bioreactors for novel vaccine development.
However, the gene modified cells segment is anticipated to expand rapidly during 2025-2034. The segment is propelled by a huge demand for cell and gene therapies, which are widely used in oncology and rare genetic disorders. Alongside, single-use bioreactors encompass properties to control specific parameters precisely, such as temperature, pH, and oxygen levels, ensuring optimal expansion conditions for gene-modified cells. Examples like wave bioreactors are applied in a rocking motion to evolve a wave-like movement in the culture bag, ensuring efficient mixing and gas exchange.
By application analysis
Which Application Dominated the Single-Use Bioreactors Market in 2024?
The research and development (R&D) or process development segment held the biggest revenue share of the market in 2024. Across the market, the segment consists of broader utilization of single-use bioreactors in R&D to standardize conditions for scaling up production and confirm continuous effectiveness from lab to industrial level. Apart from this, these bioreactors are favourable for small-scale R&D, particularly in testing new cell lines and media formulation. As well as phenomenal advances in single-use bioreactor technology, like optimized mixing and oxygen transfer, are boosting their adoption in R&D.
And, the bioproduction segment is predicted to register rapid expansion in the respective market. The feasibility of single-use bioreactors during the delivery, with maintaining their sterility and ready for installation features are streamlines the bioproduction setup process. Other properties of these bioreactors are impacting bioproduction, including the usage of polymers and plastics that must be compatible with cell culture, which are sterilized by the application of gamma irradiation to avoid pH fluctuations. This expansion of bioproduction will also comprise non-invasive sensors that can monitor temperature, dissolved oxygen, and pH, further minimizing the risk of contamination.
By usage analysis
Why did the Lab-scale Production Segment Hold a Major Share of the Market in 2024?
In the single-use bioreactors market, the lab-scale production segment was dominant in 2024. Currently, the increasing focus on the development of precision medicine, which necessitates smaller batch sizes and customized therapies, is immensely influencing this segment expansion. Additionally, the single-use bioreactors greatly support the transformation and optimization of cell lines for different biopharmaceutical applications. In case of lab-scale production, a wide range of profitable approaches involve using these bioreactors, like in research, preclinical studies, or clinical trials.
On the other hand, the large-scale production segment is predicted to expand at a notable CAGR during 2025-2034. Various Contract Development and Manufacturing Organizations (CDMOs) and small and medium-sized enterprises (SMEs) are broadly adopting single-use bioreactors due to their cost-effectiveness and minimal operational spending. Furthermore, consistent advances in single-use technologies, like larger-scale bioreactors and improved mixing and oxygen transfer capabilities, are propelling overall market development. Adoption of highly sophisticated sensor technologies and automation is further integrated into single-use systems to expand process monitoring and control, with allowance of process analytical technology (PAT).
By end-use analysis
How did the CMOs & CROs Segment Dominate the Market in 2024?
The CMOs & CROs segment led the single-use bioreactors market in 2024. Primarily, contributing factors are a rise in outsourcing and the advantages of single-use techniques, including their flexibility, inexpensiveness, and accelerated timelines in biopharmaceutical development and manufacturing. However, CMOs and CROs are leveraging these approaches for strong biopharmaceutical production, especially for a variety of product portfolios and quick campaign turnarounds.
The pharmaceutical and biopharmaceutical companies segment is anticipated to register notable growth in the future. Many global providers of single-use technology, particularly single-use bioreactors, are also highly enabling optimization of solutions for mammalian cell culture, high cell-density processes, and microcarrier-based processes. Whereas some companies are offering scientific instrumentation, reagents, consumables, and software, with the inclusion of single-use bioreactors for numerous applications. In several companies, single-use bioreactors are suitable for biopharmaceutical production, mainly for the production of monoclonal antibodies and other biologics.
Recent Developments
- In February 2025, US-based Sunflower Therapeutics announced its foremost distribution agreement with PharmNXT Biotech, an Indian bioprocessing company, to launch its Daisy Petal Perfusion Bioreactor System in Asia, a crucial step in the company’s ongoing product commercialization.
- In September 2024, Culture Biosciences, a developer of automated bioprocess development tools, collaborated with Google Cloud, which will integrate Culture’s real-time data monitoring and cloud-connected bioreactors with Gemini AI and other advanced data tools designed by Google.
Browse More Insights of Towards Healthcare:
The global single cell sequencing market was valued at US$ 1.63 billion in 2024 and is projected to reach US$ 1.88 billion in 2025. By 2034, the market is anticipated to surpass US$ 6.65 billion, expanding at a steady CAGR of 15.05%.
The global single-use assemblies market stood at USD 13.25 billion in 2024 and is forecast to grow to USD 15.39 billion in 2025. It is expected to achieve nearly USD 58.44 billion by 2034, progressing at a CAGR of 16.15% between 2025 and 2034.
The global single-cell biotherapeutics market is witnessing an upward growth trend and is expected to generate significant revenue, potentially scaling into the hundreds of millions over the forecast period of 2025–2034.
The global single-use downstream bioprocessing market was valued at USD 1.57 billion in 2024, rising to USD 1.79 billion in 2025, and is estimated to reach around USD 5.9 billion by 2034, advancing at a CAGR of 14.24% during 2025–2034.
The global single-use sensors market was worth USD 0.47 billion in 2024 and is projected to increase to USD 0.54 billion in 2025. By 2034, it is expected to climb to about USD 1.86 billion, recording a CAGR of 15.04% between 2025 and 2034.
The global single cell analysis market reached USD 5.19 billion in 2024 and is expected to grow to USD 6.16 billion in 2025. By 2034, the market is forecast to attain USD 29.15 billion, expanding rapidly at a CAGR of 18.74% over the period.
The global single nucleotide polymorphism (SNP) genotyping market was valued at USD 6.48 billion in 2024, increasing to USD 7.24 billion in 2025, and is projected to reach nearly USD 19.48 billion by 2034, with a CAGR of 11.7% between 2025 and 2034.
The global single-cell omics market accounted for US$ 1.94 billion in 2024, growing to US$ 2.35 billion in 2025. By 2034, it is forecast to generate around US$ 12.05 billion, advancing at a CAGR of 16.14%.
The global single-use pump market was valued at US$ 451.81 million in 2023 and is projected to reach approximately US$ 2.13 billion by 2034, expanding at a CAGR of 15.95% during 2024–2034.
The global single-use bioprocessing market is anticipated to grow from USD 30.77 billion in 2025 to nearly USD 112.2 billion by 2034, registering a CAGR of 15.46% over the forecast period.
Single-Use Bioreactors Market Key Players
- Sartorius Stedim Biotech
- Thermo Fisher Scientific
- Danaher
- Merck KgaA
- Celltainer Biotech BV
- Getinge AB
- Eppendorf AG
- Cellexus
- PBS Biotech Inc.
- Distek Inc.
- ABEC
- Able Corporation & Biott Corporation
- G&G Technologies Inc.
- Solida Biotech GmbH
- Satake Chemical Equipment Mfg., Ltd.
- Stobbe Pharma GmbH
- bbi-biotech GmbH
Segments Covered in The Report
By Product
- Single-use Bioreactor Systems
- Up to 10L
- 11-100L
- 101-500L
- 501-1500L
- Above 1500L
- Single-use media bags
- 2D Bags
- 3D Bags
- Others
- Single-use Filtration Assemblies
- Other Products
By Type
- Stirred-tank SUBs
- Wave-induced SUBs
- Bubble-column SUBs
- Other SUBs
By Type of Cell
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
- Other Cells
By Molecule Type
- Monoclonal Antibodies
- Vaccines
- Gene Modified Cells
- Stem Cells
- Other Molecules
By Application
- Research and Development (R&D) or Process Development
- Bioproduction
By Usage Type
- Lab-scale Production
- Pilot-scale Production
- Large-scale Production
By End-use
- Pharmaceutical & Biopharmaceutical Companies
- CROs & CMOs
- Academic & Research Institutes
By Region
- North America
- US
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5447
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
